These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37790509)

  • 1. Systematic investigation of chemo-immunotherapy synergism to shift anti-PD-1 resistance in cancer.
    Wang Y; Pattarayan D; Huang H; Zhao Y; Li S; Wang Y; Zhang M; Li S; Yang D
    Res Sq; 2023 Sep; ():. PubMed ID: 37790509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic investigation of chemo-immunotherapy synergism to shift anti-PD-1 resistance in cancer.
    Wang Y; Pattarayan D; Huang H; Zhao Y; Li S; Wang Y; Zhang M; Li S; Yang D
    Nat Commun; 2024 Apr; 15(1):3178. PubMed ID: 38609378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy-induced apoptosis, autophagy and cell cycle arrest are key drivers of synergy in chemo-immunotherapy of epithelial ovarian cancer.
    Wahba J; Natoli M; Whilding LM; Parente-Pereira AC; Jung Y; Zona S; Lam EW; Smith JR; Maher J; Ghaem-Maghami S
    Cancer Immunol Immunother; 2018 Nov; 67(11):1753-1765. PubMed ID: 30167862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis.
    Wenfan F; Manman X; Xingyuan S; Zeyong J; Jian Z; Lu D
    Ther Adv Chronic Dis; 2023; 14():20406223231189224. PubMed ID: 37841212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-Analysis.
    Liu L; Bai H; Wang C; Seery S; Wang Z; Duan J; Li S; Xue P; Wang G; Sun Y; Du X; Zhang X; Ma Z; Wang J
    J Thorac Oncol; 2021 Jul; 16(7):1099-1117. PubMed ID: 33839365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line immune-based combination therapies for advanced non-small cell lung cancer: A Bayesian network meta-analysis.
    Mao Z; Jiang P; Zhang Y; Li Y; Jia X; Wang Q; Jiao M; Jiang L; Shen Y; Guo H
    Cancer Med; 2021 Dec; 10(24):9139-9155. PubMed ID: 34747149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adding combination immunotherapy consisting of cancer vaccine, anti-PD-1 and anti-CSF1R antibodies to gemcitabine improves anti-tumor efficacy in murine model of pancreatic ductal adenocarcinoma.
    Saung MT; Zheng L
    Ann Pancreat Cancer; 2019 Dec; 2():. PubMed ID: 32405624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic profiling of immune microenvironment during anti-PD-1 immunotherapy for head and neck squamous cell carcinoma: the IPRICE study.
    Hélène C; Conrad O; Pflumio C; Borel C; Voegelin M; Bernard A; Schultz P; Onea MA; Jung A; Martin S; Burgy M
    BMC Cancer; 2023 Dec; 23(1):1209. PubMed ID: 38066522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual Synergistic Tumor-Specific Polymeric Nanoparticles for Efficient Chemo-Immunotherapy.
    Xiang J; Liu K; Xu H; Zhao Z; Piao Y; Shao S; Tang J; Shen Y; Zhou Z
    Adv Sci (Weinh); 2023 Oct; 10(29):e2301216. PubMed ID: 37551065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DTX@VTX NPs synergy PD-L1 immune checkpoint nanoinhibitor to reshape immunosuppressive tumor microenvironment for enhancing chemo-immunotherapy.
    Zhang R; Wan Y; Lv H; Li F; Lee CS
    J Mater Chem B; 2021 Sep; 9(36):7544-7556. PubMed ID: 34551052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An experimental model of anti-PD-1 resistance exhibits activation of TGFß and Notch pathways and is sensitive to local mRNA immunotherapy.
    Bernardo M; Tolstykh T; Zhang YA; Bangari DS; Cao H; Heyl KA; Lee JS; Malkova NV; Malley K; Marquez E; Pollard J; Qu H; Roberts E; Ryan S; Singh K; Sun F; Wang E; Bahjat K; Wiederschain D; Wagenaar TR
    Oncoimmunology; 2021 Mar; 10(1):1881268. PubMed ID: 33796402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data.
    Pérol M; Felip E; Dafni U; Polito L; Pal N; Tsourti Z; Ton TGN; Merritt D; Morris S; Stahel R; Peters S
    Ann Oncol; 2022 May; 33(5):511-521. PubMed ID: 35218887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Traditional Treatment Approaches and Role of Immunotherapy in Lung Malignancy and Mesothelioma.
    Tamanna MT; Egbune C
    Cancer Treat Res; 2023; 185():79-89. PubMed ID: 37306905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma.
    Xu J; Zheng Q; Cheng X; Hu S; Zhang C; Zhou X; Sun P; Wang W; Su Z; Zou T; Song Z; Xia Y; Yi X; Gao Y
    J Nanobiotechnology; 2021 Oct; 19(1):355. PubMed ID: 34717654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer - a non-randomized phase II clinical trial.
    Rutten VC; Salhi Y; Robbrecht GJ; de Wit R; van Leenders GJLH; Zuiverloon TCM; Boormans JL
    BMC Cancer; 2023 Jun; 23(1):539. PubMed ID: 37312054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer.
    Alì G; Poma AM; Di Stefano I; Zirafa CC; Lenzini A; Martinelli G; Romano G; Chella A; Baldini E; Melfi F; Fontanini G
    Front Oncol; 2023; 13():1115156. PubMed ID: 36845706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discontinuation risk from adverse events: immunotherapy alone vs. combined with chemotherapy: a systematic review and network meta-analysis.
    Shin S; Moon J; Oum C; Kim S; Cho SI; Lim Y; Ock CY; Shin S
    BMC Cancer; 2024 Jan; 24(1):152. PubMed ID: 38291376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
    Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT).
    Gridelli C; Peters S; Mok T; Garassino M; Paz-Ares L; Attili I; de Marinis F
    Lung Cancer; 2024 Jan; 187():107441. PubMed ID: 38141488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular risks of chemo-immunotherapy for lung cancer: A population-based cohort study.
    Chan JSK; Tang P; Ng K; Dee EC; Lee TTL; Chou OHI; Lee YHA; Lau DHH; Liu T; Tse G
    Lung Cancer; 2022 Dec; 174():67-70. PubMed ID: 36334359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.